New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis

ConferencepositiveRezpegaldesleukinPositive

AI Analysis

Summary

Nektar Therapeutics presented late-breaking biomarker data at EADV Congress 2026 demonstrating early molecular responses to Rezpegaldesleukin in atopic dermatitis patients, with improvements detected as early as Week 2 that correlated with clinical response.

Outcome Details

Biomarker data showing early molecular responses across multiple immune pathways dysregulated in atopic dermatitis; improvements detected as early as Week 2 correlated with subsequent clinical response

Importance:5/10

Sentiment:

0.65

atopic dermatitisbiomarker dataclinical responseimmunologyconference presentationEADV 2026

Related Companies

$NKTR

Read the original article

Published by PR Newswire Biotech on September 30, 2026 2:30 PM

Read Original